pharma · Myelofibrosis · Acute Myeloid Leukemia
Karyopharm Therapeutics
Karyopharm Therapeutics Inc
Karyopharm Therapeutics clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 85 Wells Avenue, Newton, MA 02459, US
- Employees
- 313
- Programs
- 82
- Drugs
- 53
- Patents
- 38
Karyopharm Therapeutics projects
7 ClinicalTrials.gov programs sponsored by Karyopharm Therapeutics.
Karyopharm Therapeutics has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
SELINEXOR for endometrial cancer
Karyopharm Therapeutics Inc
endometrial cancer
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Dedifferentiated Liposarcoma
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Endometrial Cancer
2 trials -
Selinexor
Karyopharm Therapeutics Inc
Multiple Myeloma
12 trials -
Selinexor (combination therapy)
Karyopharm Therapeutics Inc
Relapsed/Refractory Diffuse Large B-cell Lymphoma
1 trial -
XPORT-DLBCL-30
Karyopharm Therapeutics Inc
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)
1 trial -
XPORT-MF-034
Karyopharm Therapeutics Inc
Treatment naïve patients with MF
1 trial
Frequently asked questions
How many clinical projects does Karyopharm Therapeutics have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.